Merck Serono Phase III Trial Extension For Safinamide In Parkinson’s Misses Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will pursue lower dose in future clinical trials, firm tells “The Pink Sheet” DAILY.